Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Introduction
00:00 • 2min
The First Version of the Protocol 11 Years Ago
01:39 • 2min
The Meropenem Administration Strategy in a Patient With a Rareonus Ventilator Assembled Pneumonia
03:11 • 4min
Beta-Lactams and Bacteria Resistance
07:04 • 5min
Meropenem and the Mercy Trial
11:37 • 2min
The Advantages and Disadvantages of a Composite Primary Outcome
14:07 • 4min
The Effects of Carmopennum on Secondary Infection
17:45 • 4min
Meropanin and the Mercy Trial
21:25 • 4min
The Effect of Continuous Strategy on Primary Outcomes of Meropenem Administration
25:07 • 4min
The Effects of Beta-Lactams Meropelan on Mortality
28:54 • 3min
The Negative Effects of Continuous Infusion on Mortality and Emergence of Drug Resistant Bacteria
31:53 • 2min
The Mercy Trial
33:52 • 2min
The Pros and Cons of Continuous Infusion
36:04 • 4min
The Effects of Continuous Infusion on Sepsis Mortality
39:36 • 3min
The Effect of Resistance on Drug Delivery
42:46 • 2min
The Heterogeneity of Treatment Effects in Sepsis Trials
45:04 • 4min
The Impact of Continuous Infusion on Mortality
49:06 • 3min
The Bbling-Free Trial Is Complete
51:50 • 2min
The Effects of Continuous Inclusion on Mortality
53:46 • 4min
Meropenum: A Second Line Antibiotic for Sepsis
58:01 • 3min
The Effects of Meropenem on Mortality
01:01:19 • 4min
The Multi-Centre Trial of Antibiotics
01:05:31 • 4min
The Effects of Beta-Lactam Therapy on Immunosuppression
01:09:04 • 3min
The Effects of Randomization on Antimicrobial Resistance in an ICU
01:11:37 • 6min
The Pros and Cons of the MACE Trial
01:17:17 • 4min
The Importance of Research Inclusion in Sepsis Trials
01:21:21 • 3min
The Effects of Meropenum on Gram Positive Bacteria
01:24:48 • 5min